<DOC>
	<DOC>NCT00556270</DOC>
	<brief_summary>The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).</brief_summary>
	<brief_title>Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain</brief_title>
	<detailed_description />
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Main inclusion criteria: Patients with severe, chronic pain Main exclusion criteria: Hypersensitivity of fentanyl Coadministration of monoaminooxidaseinhibitors Pregnancy Respiratory depression Chronic obstructive pulmonary disease (COPD) Drug abuse Impairment of CNS functions Other criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pain</keyword>
	<keyword>fentanyl</keyword>
	<keyword>transdermal patch</keyword>
</DOC>